James Lancaster’s Post

CytoReason just secured $80 million in our Series B funding round. It’s a big deal for us, because some of the investors are top leaders in their industries – Pfizer (pharma), NVIDIA (tech), Thermo Fisher Scientific (life sciences). And it’s a big deal because reality these days is not so simple. Not in Israel (we all know why) and not globally, with high interest rates and major economic and regulatory challenges. Just look at these contrasting headlines from one local newspaper’s feed today. This is the story in a nutshell. We’re celebrating today, but trust me, it hasn’t been easy for us either. And lots of challenges and opportunities lie ahead. Still, throughout this journey, I’ve learned 2 valuable lessons: 1. Persistence is the name of the game – even when the odds seem insurmountable, there’s always a way forward. And thanks David H. for teaching me this lesson! Now I get why you so relate to Vince Lombardi’s quote “Winners never quit. Quitters never win.” 2. Surround yourself with a great team – there’s no way in the world we’d be able to do this without the incredible, daily efforts of the company’s finance team. Thank you Yana Bronstein Nidam & Michael Frei! You’re the living proof that teamwork is not just a statement written on our team’s core values list, but a true state of mind. With all due modesty, I feel this is also a major personal and professional achievement. But the one person, at least for me, who played the most pivotal role in this achievement is Michal Levy Ganiel. Thanks Michal for your ongoing support! Especially for putting up with the late-night conference calls and the long-hour weekends. I suppose it will be a bit less crazy now…

Breaking news! James Hussey, CEO at Seneca Therapeutics, Inc. will join The Keiretsu Family Office Forum as a part of the Family Office Investment Outlook Panel. Register now to hear his thoughts about the current landscape of family office investment: https://lnkd.in/dynZpRff #InvestorCapitalExpo #FamilyOfficeForum #AngelEcosystem #InvestorCapitalExpo2024 #AngelInvesting #AngelCommunity

Anyone else see this shareholder letter to Pacira BioSciences, Inc.? Pull quote: "In our view, Pacira’s Board demonstrates an ineffective capital allocation strategy, maintains a dismal M&A track record and lacks strategic oversight. As shareholders, it is not our preference to discuss these issues publicly nor to endeavor to overhaul the Board. Present circumstances – including the dramatic collapse of Pacira’s stock price and how the Company has handled patent litigation and its communication to shareholders regarding the situation thus far – have pushed us to publish this letter." Read full letter here: https://lnkd.in/eWpa65hy We want a rising tide to bring up ALL boats in our space, if you were a consultant here how would you advise? #devicenation

🟠 First Day Jitters or Ominous Signs? 🟠 It’s hard not to raise an eyebrow at Alumis Inc.’s rocky debut. A 17% nosedive on Day 1 isn’t exactly the ringing endorsement most IPOs aspire to, especially when you had to downsize your offering to drum up $250 million, padding that timid show with a private placement. Name a starker telltale sign that the market might be losing its appetite for clinical stage biopharma. There's a brutal reality beneath this spectacle: investor confidence isn’t bought in bulk. 🔸 Now, let’s face the facts: - **Shrinking IPO Size:** Going smaller with the public offering to garner even a whisper of interest? Sounds desperate, not promising. - **Launch Day Plummet:** A significant price drop on debut is a hard-to-miss red flag that might aim to reveal a stormy road ahead. 💼 **The Prediction Game:** I smell future turbulence for Alumis unless they showcase some groundbreaking clinical trial milestones—and fast. Shares are a heartbeat away from being branded toxic assets if clinical outcomes don't shift sentiment soon. Truly resilient organizations pivot quickly when faced with such stark market critiques. Alumis will need more than just scientific novelty; they’ll require visionary marketing and perhaps a revisit to burn rate strategies. Fingers crossed they don’t just become another cautionary tale for burgeoning biopharma IPOs. Sacrificial or Survivor? The next few months will tell. #Biopharma #IPO #MarketWatch #InvestmentInsights #PotentialInPeril https://lnkd.in/emdgfXDV

Impact Biomedical, Inc. Announces Pricing of Initial Public Offering    Today marks a significant milestone for Impact BioMedical Inc. (NYSE American: IBO) as we announce the pricing of our initial public offering of 1,500,000 shares at $3.00 per share. Starting today, September 16, 2024, our shares will begin trading on the NYSE American Market under the ticker symbol “IBO.”   The offering is expected to close on September 17, 2024, with an additional 45-day option for underwriters to purchase up to 225,000 more shares, further bolstering our public debut.   As we embark on this exciting chapter, Impact BioMedical remains committed to discovering and developing innovative solutions in human healthcare and wellness. This IPO is a testament to our vision and continued growth as we bring new offerings to market.   https://lnkd.in/eii5sHPN   #ImpactBioMedical #IPO #HealthcareInnovation #NYSE #LifeSciences #IBO Revere Securities

Impact Biomedical, Inc. Announces Pricing of Initial Public Offering    Today marks a significant milestone for Impact BioMedical Inc. (NYSE American: IBO) as we announce the pricing of our initial public offering of 1,500,000 shares at $3.00 per share. Starting today, September 16, 2024, our shares will begin trading on the NYSE American Market under the ticker symbol “IBO.”   The offering is expected to close on September 17, 2024, with an additional 45-day option for underwriters to purchase up to 225,000 more shares, further bolstering our public debut.   As we embark on this exciting chapter, Impact BioMedical remains committed to discovering and developing innovative solutions in human healthcare and wellness. This IPO is a testament to our vision and continued growth as we bring new offerings to market.   https://lnkd.in/eT79gSUK   #ImpactBioMedical #IPO #HealthcareInnovation #NYSE #LifeSciences #IBO Revere Securities

108 Securities Presents Erez Tetro CEO, VVT Medical October 22,2024 On Today’s 108 Securities Quick Cast, Michael Crowley CEO and Jay Bertram CMO, welcome Erez Tetro CEO of VVT medical. Michael and Jay ask Erez many questions that focus on the Varicose Vein Market and various other questions that help listeners truly understand better this opportunity. Listen in for this informative update.   Soundcloud: https://lnkd.in/eKKdxv3P For a Full Profile View and opportunity please visit : www.108securities.com #crowdfunding #stocks #investments #InvestmentOpportunity #Opportunities #gopublic #equity #EMD #108securities #Crowdfunding #platform #invest

📢 Dive into the latest CEO interview with Patrik Eschricht by BioStock - Connecting Innovation and Capital, covering his view on PHI's new dual listing on the US OTC Markets Group, and what it means for our Swedish shareholders. He also comments on recent events at Wake Forest Institute for Regenerative Medicine and the upcoming redemption of TO 4 warrants in October. Exciting times ahead! Read the full interview 🔗 https://lnkd.in/gExPv_CZ #PHI #duallisting #OTCQB #WFIRM #CEOinsights #investornews

Protean Small Cap again outperformed its benchmark in October. -2.11% means it is up 24.8% year to date and 39.7% since launch. It has outperformed the Carnegie Nordic Small Cap Index by 21.4%. Protean Select -1.7% takes the YTD performance to 10.3%, and +25.2% since launch. All figures net of fees. This month's partner letter covers how to be wrong in style, our recent hires, and thoughts on a few cases - why we confuse frequency with magnitude in Getinge as an example. And, as always, some details on holdings and trades. Thank you for being an investor. ⚠ Investments are risky. You may lose money.

Futura Medical shares rise on $5m US milestone payment #AIM #OTC #FUM #FAMDF. Futura Medical PLC (AIM:FUM, OTC:FAMDF) shares rose in early trading after the company secured a $5 million milestone payment following the US launch of its erectile dysfunction gel, Eroxon. The payment was triggered as distribution partner Haleon began fulfilling online pre-orders and making the product available in US retail stores. Eroxon is the first over-the-counter treatment for erectile dysfunction to be sold in the US, and Futura expects to receive the payment soon. In the first hour of trading the stock was up a penny at 33.55p. Stifel reckons peak Eroxon sales will be... http://ow.ly/flzx105La3I